It's still a fact that we have a golden opportunity to deliver compelling technology to the world and to build a strong recurring nanoparticles revenue business (the latter is in its infancy and growing).
Four clinical sites recruiting from day one I believe would've assisted greatly in the trial living up to its hopes and expectations instead of the one then two sites in Victoria and later the third site established in QLD with an imminent fourth site in NSW to be announced any day now.
The time taken to recruit patients in our particular trial disclosed something to me that I was previously unaware of, and that something is the difficulty in recruiting for our trial; I don't think you can ever be too sure on how a recruiting campaign will behave...with hindsight, we can now see how the benefit of four clinical sites screening and recruiting from day one would've helped our cause immensely...especially when IBX (in its nascent stage) is also having to work through the Covid pandemic.
There are many who have complained about the usefulness of management communication and guidance sharing to date, but I guess if there's no news there's no news and I'd rather that than a Co that provides just a promotional synopsis of the Co's aspiration. It's clear now that the type of investor base that IBX has attracted has little to no tolerance for delays and others that don't have the full understanding of the realities and vagaries that can occur in our complex sector. And hence we/they become poor backers of the Co when course corrections are required or delays in progress occur.
I'm continuing to 'Hold' as I'm hopeful that we can transition into a bigger and better Co...that said, I don't want or expect a publicly listed Co to publicly confess and articulate its lessons learned, as it never pays to bleed when you swim with sharks.
IBX Price at posting:
6.2¢ Sentiment: Buy Disclosure: Held
